411 related articles for article (PubMed ID: 17761983)
21. Proteogenomic Analysis of Salivary Adenoid Cystic Carcinomas Defines Molecular Subtypes and Identifies Therapeutic Targets.
Ferrarotto R; Mitani Y; McGrail DJ; Li K; Karpinets TV; Bell D; Frank SJ; Song X; Kupferman ME; Liu B; Lee JJ; Glisson BS; Zhang J; Aster JC; Lin SY; Futreal PA; Heymach JV; El-Naggar AK
Clin Cancer Res; 2021 Feb; 27(3):852-864. PubMed ID: 33172898
[TBL] [Abstract][Full Text] [Related]
22. Immunohistochemical study of epidermal growth factor receptor in adenoid cystic carcinoma of salivary gland origin.
Vered M; Braunstein E; Buchner A
Head Neck; 2002 Jul; 24(7):632-6. PubMed ID: 12112535
[TBL] [Abstract][Full Text] [Related]
23. Expression of Autophagy and Reactive Oxygen Species-Related Proteins in Lacrimal Gland Adenoid Cystic Carcinoma.
Koo JS; Kim JW; Yoon JS
Yonsei Med J; 2016 Mar; 57(2):482-9. PubMed ID: 26847304
[TBL] [Abstract][Full Text] [Related]
24. Association between high expression of phosphorylated Akt and mammalian target of rapamycin and improved survival in salivary gland adenoid cystic carcinoma.
Ouyang DQ; Liang LZ; Ke ZF; Zheng GS; Weng DS; Yang WF; Su YX; Liao GQ
Head Neck; 2017 Jun; 39(6):1145-1154. PubMed ID: 28230926
[TBL] [Abstract][Full Text] [Related]
25. Ataxia-Telangiectasia-Mutated Protein Expression as a Prognostic Marker in Adenoid Cystic Carcinoma of the Salivary Glands.
Bazarsad S; Kim JY; Zhang X; Kim KY; Lee DY; Ryu MH; Kim J
Yonsei Med J; 2018 Aug; 59(6):717-726. PubMed ID: 29978608
[TBL] [Abstract][Full Text] [Related]
26. Clinicopathological features of salivary and non-salivary adenoid cystic carcinomas.
Lin YC; Chen KC; Lin CH; Kuo KT; Ko JY; Hong RL
Int J Oral Maxillofac Surg; 2012 Mar; 41(3):354-60. PubMed ID: 22230288
[TBL] [Abstract][Full Text] [Related]
27. Expression of metabolism-related proteins in lacrimal gland adenoid cystic carcinoma.
Koo JS; Yoon JS
Am J Clin Pathol; 2015 Apr; 143(4):584-92. PubMed ID: 25780012
[TBL] [Abstract][Full Text] [Related]
28. A phase II study of Imatinib for advanced adenoid cystic carcinoma of head and neck salivary glands.
Pfeffer MR; Talmi Y; Catane R; Symon Z; Yosepovitch A; Levitt M
Oral Oncol; 2007 Jan; 43(1):33-6. PubMed ID: 16757202
[TBL] [Abstract][Full Text] [Related]
29. Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies.
Spector NL; Xia W; Burris H; Hurwitz H; Dees EC; Dowlati A; O'Neil B; Overmoyer B; Marcom PK; Blackwell KL; Smith DA; Koch KM; Stead A; Mangum S; Ellis MJ; Liu L; Man AK; Bremer TM; Harris J; Bacus S
J Clin Oncol; 2005 Apr; 23(11):2502-12. PubMed ID: 15684311
[TBL] [Abstract][Full Text] [Related]
30. Tamoxifen for salivary gland adenoid cystic carcinoma: report of two cases.
Elkin AD; Jacobs CD
J Cancer Res Clin Oncol; 2008 Oct; 134(10):1151-3. PubMed ID: 18347813
[TBL] [Abstract][Full Text] [Related]
31. Toll-like receptor 5 and 7 expression in adenoid cystic carcinoma of major salivary glands.
Hirvonen K; Bäck L; Haglund C; Leivo I; Jouhi L; Mäkitie AA; Hagström J
Tumour Biol; 2016 Aug; 37(8):10959-64. PubMed ID: 26888781
[TBL] [Abstract][Full Text] [Related]
32. Imatinib mesylate as treatment for adenoid cystic carcinoma of the salivary glands: report of two successfully treated cases.
Alcedo JC; Fábrega JM; Arosemena JR; Urrutia A
Head Neck; 2004 Sep; 26(9):829-31. PubMed ID: 15350030
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of nelfinavir as monotherapy in refractory adenoid cystic carcinoma: Results of a phase II clinical trial.
Hoover AC; Milhem MM; Anderson CM; Sun W; Smith BJ; Hoffman HT; Buatti JM
Head Neck; 2015 May; 37(5):722-6. PubMed ID: 24596143
[TBL] [Abstract][Full Text] [Related]
34. Protein expression profiling identifies maspin and stathmin as potential biomarkers of adenoid cystic carcinoma of the salivary glands.
Nakashima D; Uzawa K; Kasamatsu A; Koike H; Endo Y; Saito K; Hashitani S; Numata T; Urade M; Tanzawa H
Int J Cancer; 2006 Feb; 118(3):704-13. PubMed ID: 16094606
[TBL] [Abstract][Full Text] [Related]
35. Analysis and significance of c-MET expression in adenoid cystic carcinoma of the salivary gland.
Bell D; Ferrarotto R; Fox MD; Roberts D; Hanna EY; Weber RS; El-Naggar AK
Cancer Biol Ther; 2015; 16(6):834-8. PubMed ID: 25923130
[TBL] [Abstract][Full Text] [Related]
36. Phase II trial of taxol in salivary gland malignancies (E1394): a trial of the Eastern Cooperative Oncology Group.
Gilbert J; Li Y; Pinto HA; Jennings T; Kies MS; Silverman P; Forastiere AA
Head Neck; 2006 Mar; 28(3):197-204. PubMed ID: 16470745
[TBL] [Abstract][Full Text] [Related]
37. MicroRNA155 in the growth and invasion of salivary adenoid cystic carcinoma.
Liu L; Hu Y; Fu J; Yang X; Zhang Z
J Oral Pathol Med; 2013 Feb; 42(2):140-7. PubMed ID: 22823535
[TBL] [Abstract][Full Text] [Related]
38. A phase II study of lapatinib in recurrent/metastatic squamous cell carcinoma of the head and neck.
de Souza JA; Davis DW; Zhang Y; Khattri A; Seiwert TY; Aktolga S; Wong SJ; Kozloff MF; Nattam S; Lingen MW; Kunnavakkam R; Stenson KM; Blair EA; Bozeman J; Dancey JE; Vokes EE; Cohen EE
Clin Cancer Res; 2012 Apr; 18(8):2336-43. PubMed ID: 22371453
[TBL] [Abstract][Full Text] [Related]
39. A phase 2 study of MK-2206 in patients with incurable adenoid cystic carcinoma (Alliance A091104).
Ho AL; Foster NR; Deraje Vasudeva S; Katabi N; Antonescu CR; Frenette GP; Pfister DG; Erlichman C; Schwartz GK
Cancer; 2024 Mar; 130(5):702-712. PubMed ID: 37947157
[TBL] [Abstract][Full Text] [Related]
40. Phase 2 study of dovitinib in patients with metastatic or unresectable adenoid cystic carcinoma.
Keam B; Kim SB; Shin SH; Cho BC; Lee KW; Kim MK; Yun HJ; Lee SH; Yoon DH; Bang YJ
Cancer; 2015 Aug; 121(15):2612-7. PubMed ID: 25903089
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
